Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies

Sponsor
Ossium Health, Inc.
Study ID
NCT07710781
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Ossium HPC, Marrow — OTHER
    Cryopreserved deceased donor bone marrow
  • Standard of care living donor - Haplo Related — OTHER
    Haplo Related PBSC donor
  • Standard of care living donor - Mismatched Unrelated — OTHER
    Mismatched Unrelated PBSC donor

Study Details

Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.

Key Dates

First listed
Jul 17, 2026
Start date
Dec 1, 2026
Status verified
Jul 2026
Primary completion
Mar 31, 2029
Completion
Mar 31, 2031

Study Design

Enrollment
300 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ossium HPC, Marrow Donor
  • Other: Haplo Related PBSC Donor
    Standard of care living donor - Haplo Related PBSC Donor
  • Other: Mismatched unrelated PBSC Donor
    Standard of care living donor - Mismatch Unrelated PBSC Donor

Primary Outcome Measure

To determine cumulative neutrophil engraftment [ Time Frame: Day 30 ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies